Related Experiment Videos
Triplex formation at the rat neu oncogene promoter
1Center for Biotechnology, Baylor College of Medicine, The Woodlands, TX 77381.
Abstract:
Current cancer chemotherapy treatments generally act by affecting rapidly growing malignant cells. Unfortunately, they are relatively nonspecific and thus have a tendency to affect other rapidly growing normal cells in a deleterious manner. Triplex-forming oligodeoxyribonucleotides (TFOs) promise to be a new class of sequence-specific DNA-binding drugs which will target malignancies at the transcriptional level. The formation of an intermolecular triplex (triple helix) has been shown to block the binding of transcription factors and repress transcription in genes such as c-myc and that encoding the epidermal growth factor receptor. The rat neu oncogene promoter contain promoter-enhancer elements which are purine/pyrimidine rich. These enhancer elements are amenable to targeting by TFOs. the human counterpart of rat neu, HER2, is often found to be amplified or overexpressed in a variety of malignancies, such as those of the breast, lungs, ovary, colon and stomach. TFOs may proved to be the basis of effective chemotherapy drugs for these cancers. TFO binding at the "GTG" element (5'GGTGGGGGGG) and at the 'GA' element (5'GGAGGAGGAGGG) has been characterized by gel mobility shift analysis and DNase 1 footprinting. Binding has been shown to occur at a Kd as low as 10(-8) M and has been shown to be sequence specific.
Insights
Triplex-forming oligodeoxyribonucleotides (TFOs) offer a novel, sequence-specific approach to cancer chemotherapy by targeting gene transcription. This method shows promise for treating various cancers by specifically inhibiting oncogenes like HER2.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Research
Background:
- Current cancer chemotherapy lacks specificity, harming both malignant and normal cells.
- Triplex-forming oligodeoxyribonucleotides (TFOs) are a new class of sequence-specific DNA-binding drugs.
- TFOs target malignancies at the transcriptional level by forming triple helices.
Purpose of the Study:
- To investigate TFOs as a novel chemotherapy strategy targeting oncogenes.
- To evaluate TFOs' potential in inhibiting transcription of key cancer-related genes.
- To explore TFOs for treating HER2-amplified malignancies.
Main Methods:
- Gel mobility shift analysis to characterize TFO binding.
- DNase 1 footprinting to determine binding sites and specificity.
- Investigating TFO binding to purine/pyrimidine-rich enhancer elements in oncogene promoters.
Main Results:
- TFO binding to specific elements (e.g., "GTG" and "GA" elements) was characterized.
- High-affinity binding was observed, with dissociation constants (Kd) as low as 10(-8) M.
- Sequence-specific binding of TFOs was confirmed.
Conclusions:
- TFOs can specifically target and bind to oncogene promoter regions.
- This sequence-specific binding can repress gene transcription, offering a targeted therapy approach.
- TFOs hold potential as a basis for effective chemotherapy drugs against various cancers, including those overexpressing HER2.